CROs: pharma partners or rival, asks report?
This article was originally published in Scrip
Contract research organisations (CRO) are gaining the right skills to become direct competitors to their clients, the pharmaceutical and biotechnology business, as the level of drug discovery and development outsourcing increases in the future.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"